PMID- 35610766
OWN - NLM
STAT- MEDLINE
DCOM- 20220526
LR  - 20221207
IS  - 2639-9636 (Print)
IS  - 2639-9636 (Linking)
VI  - 37
IP  - 6
DP  - 2022 Jun 1
TI  - Semaglutide Initiation in a Type 2 Diabetes Mellitus, Post-Liver Transplant 
      Patient.
PG  - 221-226
LID - 10.4140/TCP.n.2022.221 [doi]
AB  - Objective To describe the process of initiation of semaglutide for complex 
      management of type 2 diabetes mellitus (T2DM) in a patient after liver 
      transplantation. Setting Family medicine clinic. Practice Description A family 
      medicine clinic comprising six physicians with an ambulatory care pharmacist. The 
      pharmacist has direct interaction with patients and providers within the clinic 
      assisting in the management of chronic disease states under a collaborative 
      practice agreement. Practice Innovation A 63-year-old White male with a history 
      of liver transplantation in the context of T2DM, treated with basal-bolus insulin 
      therapy, was referred by his family medicine provider to the ambulatory care 
      pharmacist for diabetes management because of a hemoglobin A1c (HbA1c) level 
      greater than 10%. Semaglutide was initiated and titrated to improve blood glucose 
      control in combination with basal-bolus insulin adjustments taking disease 
      states, cost, and health literacy into consideration. Results The addition of 
      semaglutide, over an eight-month period, assisted with glycemic control to an 
      HbA1c of less than 7%. Conclusion Semaglutide, in addition to basal-bolus insulin 
      therapy, allowed for overall improved glycemic control; however, further studies 
      are needed to evaluate efficacy because of the complexity of diabetes management 
      in this patient population. Throughout the course of treatment of patients with 
      T2DM and organ transplantation, dual monitoring of antidiabetic therapy and 
      antirejection medications is essential to reduce the risk of organ rejection.
FAU - Newell, Bradley J
AU  - Newell BJ
AD  - University of Kansas, Wichita, Kansas.
FAU - Melton, Brittany L
AU  - Melton BL
AD  - University of Kansas, Wichita, Kansas.
FAU - Burkhardt, Crystal D
AU  - Burkhardt CD
AD  - University of Kansas, Wichita, Kansas.
FAU - Ruisinger, Janelle F
AU  - Ruisinger JF
AD  - University of Kansas, Wichita, Kansas.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Sr Care Pharm
JT  - The Senior care pharmacist
JID - 101737969
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulins)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptides/therapeutic use
MH  - Glycated Hemoglobin/analysis/therapeutic use
MH  - Humans
MH  - *Insulins/therapeutic use
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
EDAT- 2022/05/26 06:00
MHDA- 2022/05/27 06:00
CRDT- 2022/05/25 00:43
PHST- 2022/05/25 00:43 [entrez]
PHST- 2022/05/26 06:00 [pubmed]
PHST- 2022/05/27 06:00 [medline]
AID - 10.4140/TCP.n.2022.221 [doi]
PST - ppublish
SO  - Sr Care Pharm. 2022 Jun 1;37(6):221-226. doi: 10.4140/TCP.n.2022.221.